Current commercial offer
The $25 headline has a monthly savings cap and eligibility limits
The official Wegovy cost page viewed August 5, 2026 lists a commercial-insurance offer of as little as $25 per month. Its footnote sets maximum savings at $100 per month, excludes government beneficiaries, and says eligibility and restrictions apply. It defines one month as one box of four pens or one bottle of 30 tablets and says Novo Nordisk may modify or cancel the program at any time. The live terms and processed pharmacy claim—not a search snippet, social post, old screenshot, or third-party coupon page—determine whether a specific fill qualifies.
- “As little as $25” means an eligible claim may be reduced within the stated cap; it does not promise that every final amount will be $25.
- Confirm the prescription, presentation, plan coverage, pharmacy network, enrollment, fill timing, and card terms before relying on an advertised amount.
- Recheck the offer after an insurance, employer, pharmacy, prescription, route, strength, or calendar-year change.
Pill and pen identity
Current Wegovy savings information covers two routes—but the offers are not interchangeable
The current manufacturer page has separate Wegovy pill and Wegovy pen tabs, and the June 2026 DailyMed label includes once-daily tablets and subcutaneous injection presentations. A valid Wegovy tablet is therefore not automatically counterfeit, and Wegovy should not be described as injection-only. Still, a pill price, pen price, authorization, pharmacy package, or refill rule should not be transferred to the other route. Match the product name, dosage form, route, strength, prescription, package, and pharmacy claim to the selected offer.
- The commercial footnote defines a month separately as 30 tablets or four pens; verify which presentation the pharmacy is processing.
- Do not assume that coverage or savings approved for tablets automatically applies to an injection presentation, or the reverse.
- Wegovy, Ozempic, Rybelsus, and compounded semaglutide share semaglutide-related language but remain distinct products and access claims.
Commercial insurance and government programs
A manufacturer savings card is not insurance and does not override plan rules
The current $25 description is presented for eligible patients with commercial prescription insurance, while the official terms exclude government beneficiaries. Medicare, Medicaid, TRICARE, VA or other government coverage, an employer retiree benefit, uninsured status, and cash-pay access can follow different rules. A card does not automatically override a benefit exclusion, prior authorization, step therapy, deductible, quantity limit, refill restriction, noncovered indication, or pharmacy-network rule.
- Ask the plan whether the exact pill or pen prescription is covered and whether prior authorization, step therapy, an indication criterion, or a preferred pharmacy applies.
- If the claim is denied, request the rejection or denial reason in writing and ask which correction, documentation, exception, or appeal process is available.
- Never enter false insurance, residency, diagnosis, age, or eligibility information to obtain a commercial offer.
Temporary self-pay prices
The manufacturer lists separate cash-pay pill and pen offers with dates and dose limits
On August 5, 2026, the official page listed tablet self-pay pricing of $149 per month for the 1.5 mg and 4 mg bottles, with the 4 mg offer available through August 31, 2026 and then listed at $199 per month. For pens, it listed $199 per month for the first two monthly fills of 0.25 mg or 0.5 mg for patients new to the offer through December 31, 2026, followed by $349 per month for listed standard pen strengths; it separately listed Wegovy HD 7.2 mg at $399 per month. These temporary amounts have distinct eligibility restrictions and do not establish what route or strength a patient should receive.
- Ask which presentation, strength, fill number, enrollment date, pharmacy channel, expiration date, and post-promotion price apply.
- Calculate total costs after the introductory fills or offer deadline and include any separate clinician, laboratory, shipping, or supply charges.
- Do not split, stretch, overlap, convert, or switch medication to fit a price tier; route and treatment decisions belong with the prescriber.
Clinical and label review
Savings eligibility does not decide whether Wegovy is medically appropriate
A paid claim or savings enrollment is not a prescription or medical clearance. The current Wegovy label has formulation-specific indications, routines, contraindications, warnings, adverse effects, and switching instructions. A clinician should review the actual indication, age, pregnancy plans, other GLP-1 or glucose-lowering medicines, gastrointestinal symptoms, dehydration or kidney concerns, gallbladder and pancreas history, diabetic eye disease, prior reactions, and upcoming procedures before selecting a route or changing treatment.
- Share all prescriptions, over-the-counter medicines, supplements, insulin or sulfonylureas, current symptoms, pregnancy plans, and procedures with the responsible clinician.
- Do not start, stop, overlap, split, substitute, or switch Wegovy pills, Wegovy pens, Ozempic, Rybelsus, or compounded semaglutide because a price changed.
- Use urgent care rather than card or insurance messaging for severe abdominal pain, repeated vomiting, severe dehydration, fainting, serious allergy symptoms, confusion, or another emergency pattern.
Compounded semaglutide and total cost
A Wegovy card does not apply to compounded semaglutide or every telehealth fee
A patient-specific compounded semaglutide prescription is not FDA-approved Wegovy, is not a generic Wegovy equivalent, and should not be submitted as a branded Wegovy savings-card claim. It has a separate prescription, pharmacy label, route, concentration, storage instructions, beyond-use date, price, and clinical review. Peptide12 lists clinician-reviewed Wegovy and semaglutide pathways, but prescribing, insurance approval, offer eligibility, pharmacy dispensing, supply, and a particular price are never guaranteed.
- Ask whether a quote covers branded Wegovy medication, compounded semaglutide, clinician services, laboratory work, pharmacy dispensing, shipping, supplies, follow-up, or a bundle.
- Verify the prescriber, pharmacy, exact product, route, label, storage, refill support, cancellation terms, and amount due before paying.
- Avoid guaranteed $25 Wegovy, no-prescription checkout, hidden pharmacy identity, research-use semaglutide sold for treatment, copied insurance answers, or compounded medication called FDA approved.